KESTRA Medical Technologies generated $30.971 million of Revenue in the three months ended July 31, 2026, up from $19.371 million a year earlier, while its net loss widened to $44.087 million. Revenue growth came from more patients using its products, but higher operating expenses and debt-extinguishment costs increased the loss.
Key Highlights
- Gross profit reached $17.498 million, compared with $8.851 million in the prior-year quarter.
- Selling, general and administrative expense rose to $48.359 million from $33.728 million.
- The company recorded a $6.304 million loss on extinguishment of Debt during the quarter.
KESTRA Medical Technologies, Ltd. (NASDAQ: KMTS) generated $30.971 million in revenue for the three months ended July 31, 2026, compared with $19.371 million in the same period of 2025. Net loss attributable to common shareholders increased to $44.087 million from $25.826 million. Loss per share was $0.75, versus $0.50 a year earlier.
Gross Profit Reaches $17.498M
Cost of revenue was $13.473 million, compared with $10.520 million in the comparable quarter. Research and Development expense increased to $6.796 million from $4.001 million, while selling, general and administrative expense reached $48.359 million compared with $33.728 million. Total operating expenses were $55.155 million, up from $37.729 million. The resulting loss from operations was $37.657 million, compared with $28.878 million in the prior-year period.
Debt Charge Deepens Quarterly Loss
Interest expense was $1.929 million, compared with $1.912 million in the prior-year quarter. Interest income was $2.125 million, versus $2.167 million. Other expense, net, was $0.272 million, compared with other income of $2.830 million in the same period of 2025. KESTRA Medical Technologies also recorded a $6.304 million loss on extinguishment of debt, while the prior-year period had no corresponding charge. Loss before income taxes was $44.037 million, compared with $25.793 million. Income tax provision was $0.050 million, versus $0.033 million.
Per-Share Loss Reaches $0.75
The weighted-average number of common shares outstanding on a basic and diluted basis was 58,566,467, compared with 51,304,599 in the prior-year quarter. Other comprehensive loss included a $0.253 million unrealized loss on marketable securities. Comprehensive loss was $44.340 million, compared with $25.826 million in the comparable period.
Outstanding Shares Near 59.6 Million
As of September 11, 2026, KESTRA Medical Technologies had 59,561,795 common shares outstanding. The company had 100,000,000 common shares authorized as of July 31, 2026. Its shareholders’ Equity was $347.355 million, compared with $358.465 million at the earlier balance-sheet date.




Please wait processing your request...